Amgen and Molecular Partners AG, a biotech company developing DARPin therapeutics, have entered a collaboration and license agreement for the clinical development and commercialization of MP0310, a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator).    Amgen obtains exclusive global development and commercial rights for MP0310. The parties will jointly evaluate ...